About Third Pole Therapeutics
Third Pole Therapeutics is a company based in Boston (United States) founded in 2014 by David Zapol. Third Pole Therapeutics has raised $87.6 million across 5 funding rounds from investors including Avenue Capital Group. Third Pole Therapeutics offers products and services including eNOfit and Inhaled Nitric Oxide Platform. Third Pole Therapeutics operates in a competitive market with competitors including Plastiflex, Vyaire, Valencia Technologies, Resvent and Rox Medical, among others.
- Headquarter Boston, United States
- Founders David Zapol
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Third Pole, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$87.6 M (USD)
in 5 rounds
-
Latest Funding Round
$16.85 M (USD), Series B
Mar 18, 2024
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Third Pole Therapeutics
Third Pole Therapeutics offers a comprehensive portfolio of products and services, including eNOfit and Inhaled Nitric Oxide Platform.
Portable system for delivering inhaled nitric oxide therapy.
Wearable device for on-demand nitric oxide delivery in treatments.
People of Third Pole Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Third Pole Therapeutics
Third Pole Therapeutics has successfully raised a total of $87.6M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $16.85 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Third Pole Therapeutics
Third Pole Therapeutics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Avenue Capital Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diversified investments in distressed debt and securities are managed globally.
|
Locked | Locked | Locked |
Investor details for Third Pole Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Third Pole Therapeutics
Investment portfolio details for Third Pole Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Third Pole Therapeutics
Detailed financials for Third Pole Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Third Pole Therapeutics Comparisons
Peer comparison for Third Pole Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Third Pole Therapeutics
Third Pole Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Plastiflex, Vyaire, Valencia Technologies, Resvent and Rox Medical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Hose systems and related components are developed and manufactured.
|
|
| Locked | Locked | Locked |
Respiratory devices for diagnostics, ventilation, and patient monitoring are developed.
|
|
| Locked | Locked | Locked |
A coin-sized neuromodulation device for hypertension treatment is developed.
|
|
| Locked | Locked | Locked |
A suite of respiratory healthcare devices is developed.
|
|
| Locked | Locked | Locked |
Develops interventional vascular therapies.
|
Detailed competitors of Third Pole Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Third Pole Therapeutics
Complete news archive for Third Pole Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Third Pole Therapeutics
Third Pole Therapeutics was founded in 2014 and raised its 1st funding round 4 years after it was founded.
Third Pole Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
David Zapol is the current CEO of Third Pole Therapeutics. They have also founded this company.
Third Pole Therapeutics is a funded company, having raised a total of $87.6M across 5 funding rounds to date.
Developer of devices for cardiopulmonary therapies. The company is developing a device offering nitric oxide (NO) from iridium electrodes for infant acute pulmonary hypertension, heart, and lung therapies. The inhaled nitric oxide therapy delivery system relaxes the blood vessels lowering the blood pressure.
Third Pole Therapeutics's top competitors include Valencia Technologies, Plastiflex and Vyaire.
Third Pole Therapeutics offers eNOfit and Inhaled Nitric Oxide Platform.
Third Pole Therapeutics has 1 investor. Key investors include Avenue Capital Group.